Diverse multidrug-resistance-modification agents inhibit cytolytic activity of natural killer cells
- 1 March 1993
- journal article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 36 (2) , 133-139
- https://doi.org/10.1007/bf01754414
Abstract
Multidrug resistance (MDR) is the phenomenon in which cultured tumor cells selected for resistance to one chemotherapeutic agent simultaneously acquire resistance to several apparently unrelated drugs. MDR in tumor cells is associated with the over-expression of P-glycoprotein, an ATP-dependent cell-membrane transport molecule. P-glycoprotein is also expressed in several normal tissues but its physiological role(s) is unknown. We recently observed that a hierarchy of MDR-like activity exists among human peripheral blood lymphocytes in the order CD8>CD4>CD20 (cytoxic/suppressor T cells, helper T cells and B cells respectively). In this study, we report that natural killer (NK) cells also express MDR-like activity. This activity could be inhibited with verapamil or solutol HS-15, two agents that reverse MDR in tumor cells. These, and four additional reversing agents, were used to investigate the possible role of P-glycoprotein in NK cells. We observed that at 10% of their IC50, five of six reversing agents inhibited NK-cell-mediated cytotoxicity; at higher (but non-toxic) doses, all six agents were inhibitory. These data suggest that NK-cell-mediated cytotoxicity may require the functional expression of an efflux molecule similar or identical to P-glycoprotein.Keywords
This publication has 28 references indexed in Scilit:
- Multidrug resistance activity in human lymphocytesHuman Immunology, 1991
- Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cellsCell, 1991
- Modulation of multidrug resistance by verapamil or mdr1 anti‐sense oligodeoxynucleotide does not change the high susceptibility to lymphokine‐activated killers in mdr‐resistant human carcinoma (LoVo) lineInternational Journal of Cancer, 1990
- Multidrug-resistance phenotype of a subpopulation of T-lymphocytes without drug selectionExperimental Cell Research, 1989
- THE BIOCHEMISTRY OF P-GLYCOPROTEIN-MEDIATED MULTIDRUG RESISTANCEAnnual Review of Biochemistry, 1989
- Expression of Multidrug Resistance Gene in Human CancersJNCI Journal of the National Cancer Institute, 1989
- Reversal of drug‐resistance in multiple myeloma with verapamilBritish Journal of Haematology, 1988
- The mdrl gene, responsible for multidrug-resistance, codes for P-glycoproteinBiochemical and Biophysical Research Communications, 1986
- Isolation and expression of a complementary DNA that confers multidrug resistanceNature, 1986
- Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell linesNature, 1985